Indaptus Therapeutics Files 8-K on Officer Changes and Exhibits
Ticker: INDP · Form: 8-K · Filed: Apr 23, 2026 · CIK: 0001857044
| Field | Detail |
|---|---|
| Company | Indaptus Therapeutics, INC. (INDP) |
| Form Type | 8-K |
| Filed Date | Apr 23, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-change, director-change, exhibit, compensation
Related Tickers: INDP
TL;DR
Indaptus Therapeutics (INDP) filed an 8-K, expect leadership/comp changes and new exhibits.
AI Summary
Indaptus Therapeutics, Inc. filed an 8-K on April 23, 2026, reporting changes in directors or officers and compensatory arrangements. The filing also includes financial statements and exhibits, with specific details likely contained within the attached documents EX-10.1 and EX-10.2.
Why It Matters
This filing indicates potential shifts in the company's leadership or executive compensation, which could impact its strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Changes in officers or directors, especially when accompanied by new compensatory arrangements, can signal significant internal shifts that may affect future performance.
Key Players & Entities
- Indaptus Therapeutics, Inc. (company) — Filer of the 8-K
- 0001857044 (company) — CIK number for Indaptus Therapeutics, Inc.
- 2026-04-23 (date) — Filing Date of the 8-K
- 2026-04-22 (date) — Period of Report for the 8-K
- EX-10.1 (document) — Exhibit filed with the 8-K
- EX-10.2 (document) — Exhibit filed with the 8-K
FAQ
What specific changes were made regarding directors or officers?
The filing indicates Item 5.02 covers 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', suggesting specific personnel changes are detailed within the report.
What information is contained in the compensatory arrangements of certain officers?
Item 5.02 of the 8-K filing addresses 'Compensatory Arrangements of Certain Officers', implying details about executive pay, bonuses, or stock options are disclosed.
What is the purpose of filing Exhibits EX-10.1 and EX-10.2?
These exhibits are typically material contracts or agreements, and their inclusion under Item 9.01 suggests they are relevant to the company's operations or financial status.
When was this 8-K filing accepted by the SEC?
The 8-K filing was accepted by the SEC on 2026-04-22 at 21:59:30.
What is Indaptus Therapeutics, Inc.'s primary business according to the SIC code?
Indaptus Therapeutics, Inc. is classified under SIC code 2834, which pertains to 'Pharmaceutical Preparations'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 23, 2026 regarding Indaptus Therapeutics, Inc. (INDP).